Ivermectin does kill lice, and it works well across all three species that infest humans: head lice, body lice, and pubic lice. In its topical form (a 0.5% lotion applied once to dry hair), it has been FDA-approved for head lice since 2012, and randomized trials consistently show cure rates in the range of 74–95% depending on formulation and whether retreatment is used. Oral ivermectin, though not officially approved for lice in most countries, outperforms several standard topical treatments in head-to-head trials. Safety at approved doses is strong, with most side effects limited to mild skin irritation or brief itching, though the oral route carries a few more considerations worth understanding.
How Ivermectin Kills Lice
Ivermectin targets a specific type of channel in the louse’s nervous system called a glutamate-gated chloride channel, or GluCl. When the drug binds to this channel, it forces the channel open and locks it in that position. Chloride ions flood into the nerve and muscle cells, which effectively paralyzes the louse. The binding is irreversible, so a louse exposed to even a small amount of ivermectin cannot recover. Lab studies on human lice confirmed that ivermectin is a potent activator of the louse GluCl receptor, triggering strong responses at very low concentrations.1PLoS Pathogens. The molecular targets of ivermectin and lotilaner in the human louse Pediculus humanus humanus: New prospects for the treatment of pediculosis – Section: Results
One important detail: ivermectin only kills lice that are alive and feeding. It has no ovicidal activity, meaning it does not kill eggs (nits). This is why a single dose of oral ivermectin often needs to be followed by a second dose about a week later. That timing lets newly hatched nymphs feed on blood containing the drug before they can mature and lay more eggs. Topical formulations work slightly differently because the lotion coats the hair shaft and can contact nymphs as they emerge, but even topical ivermectin is fundamentally an agent that kills mobile lice rather than destroying eggs in their shells.
Topical Ivermectin for Head Lice
The most studied formulation is a 0.5% ivermectin lotion applied to dry hair for ten minutes and then rinsed out. Two large randomized controlled trials published in the New England Journal of Medicine found that about 95% of patients treated with topical ivermectin were louse-free the day after treatment, and roughly 74% remained lice-free at day 15, compared with about 18% in the placebo group.2PubMed. Topical 0.5% ivermectin lotion for treatment of head lice A separate analysis of those same trials confirmed the 73.8% clearance rate at two weeks and noted that topical ivermectin was both safe and effective.3PubMed. Topical ivermectin 0.5% lotion for treatment of head lice
A dose-finding study that tested three different concentrations found that all outperformed placebo, but the 0.5% concentration achieved the highest eradication rate, around 74%, which is why that specific concentration became the commercial product.4PubMed. Assessment of the safety and efficacy of three concentrations of topical ivermectin lotion as a treatment for head lice infestation A 74% cure rate from a single application with no nit combing required may sound modest compared to the near-total kill rates of some other prescription products, but it represents a meaningful advantage for families dealing with treatment-resistant lice or who struggle with the messy, time-consuming regimens of older products.
A practical selling point of topical ivermectin is that it requires just one application and does not demand nit combing. A review of U.S. head lice management noted that topical ivermectin, along with malathion and spinosad, was among the prescription options shown to be safe and effective with a single application and no combing.5PubMed. Management of Head Louse Infestations in the United States-A Literature Review For parents who have spent hours combing nits out of a child’s hair, that convenience is not trivial.
Oral Ivermectin for Head Lice
Oral ivermectin, typically given as two doses of 200 micrograms per kilogram of body weight a week apart, has been studied extensively for head lice, especially in cases where topical treatments have failed. A landmark trial published in the New England Journal of Medicine compared oral ivermectin against malathion lotion in patients with difficult-to-treat head lice. About 95% of patients in the ivermectin group were lice-free at day 15, compared with 85% in the malathion group.6PubMed. Oral ivermectin versus malathion lotion for difficult-to-treat head lice
A systematic review and meta-analysis pooling data from multiple trials confirmed that oral ivermectin was superior to various topical therapies in achieving complete lice clearance by day 15.7International Journal of Dermatology and Venereology. Oral Ivermectin in Pediculosis Capitis: A Systematic Review and Meta-Analysis of Clinical Trials Another trial that directly compared topical and oral ivermectin head-to-head found both forms highly effective, with cure rates reaching 100% after a second treatment was given to initial non-responders.8PubMed. Assessment of topical versus oral ivermectin as a treatment for head lice
The oral route is especially useful in outbreak settings or when a family has multiple members infested, because swallowing a pill is faster and simpler than applying lotion to several heads. It also eliminates the question of whether the lotion was applied correctly and left on long enough. The main downside is that oral ivermectin for lice is off-label in most countries, so access depends on a prescriber willing to use it for this purpose.
Body Lice and Pubic Lice
Body lice, which live in clothing seams and feed on the skin, are a different species from head lice and primarily affect people experiencing homelessness or living in crowded, unsanitary conditions. A study among homeless men in Marseilles, France, gave three oral doses of ivermectin at weekly intervals and saw the total louse count in the group plummet from nearly 1,900 to just 6 over 14 days. The proportion of infested individuals dropped from about 85% to under 19%. The effect was not sustained at 45 days without continued treatment, but the initial knockdown was dramatic.9PubMed. Oral ivermectin in the treatment of body lice
Pubic lice (often called crabs) also respond to oral ivermectin. Because pubic lice feed on blood several times a day and nymphs need a blood meal almost immediately after hatching, two doses of oral ivermectin a week apart can effectively eliminate an infestation. A case series of eleven patients treated with this regimen reported no recurrences and no side effects.10Journal of the American Academy of Dermatology. Pediculosis Oral ivermectin is sometimes preferred over topical pediculicides for pubic lice because it avoids the need to apply creams to sensitive genital skin.
Safety of Topical Ivermectin
The topical 0.5% lotion has a very clean safety profile. The amount of drug that actually enters the bloodstream after a ten-minute scalp application is negligible. A pharmacokinetic study in children as young as six months found that all detected blood levels of ivermectin were below 1 nanogram per milliliter, a vanishingly small amount. Liver panels and blood counts showed no abnormalities, and the researchers concluded there was no evidence of irritation or sensitization even with repeated exposures.11PubMed. Pharmacokinetics and safety of 0.5% ivermectin lotion for head louse infestations
In a larger study of schoolchildren treated with a 0.5% ivermectin shampoo, side effects were rare and mild. At one week, fewer than 2% reported any skin irritation at all. By later follow-ups, a small percentage developed mild discomfort or itching, but the vast majority experienced nothing.12PubMed Central. Effectiveness of Topical 0.5% Ivermectin Shampoo in the Treatment of Pediculosis Capitis among School-going Female Children – Section: Results The most commonly reported side effect across studies is mild itching at the application site, affecting less than 1% of patients.
Safety of Oral Ivermectin
Oral ivermectin has been used in hundreds of millions of people worldwide, primarily for parasitic worm infections. At standard doses, a systematic review and meta-analysis of safety data found that all reported adverse events were mild or moderate. Serious events were exceptionally rare: one anaphylactic reaction in a standard-dose group and one cardiac rhythm finding in a high-dose group that was likely attributable to another medication.13Journal of Antimicrobial Chemotherapy. Safety of high-dose ivermectin: a systematic review and meta-analysis
The meta-analysis of oral ivermectin specifically for head lice noted that side effects were slightly more common in the oral group than in topical comparison groups, though the difference was not statistically significant. Reported adverse events in that lice-focused analysis did include rare seizures.7International Journal of Dermatology and Venereology. Oral Ivermectin in Pediculosis Capitis: A Systematic Review and Meta-Analysis of Clinical Trials Typical side effects from oral ivermectin at lice-treatment doses include headache, dizziness, nausea, or a mild rash, and these usually resolve within a day or two.
A more nuanced concern involves people who carry heavy burdens of certain parasitic worms, particularly the filarial worm Loa loa, which is found in parts of Central and West Africa. When ivermectin rapidly kills large numbers of these worms, the dying parasites can trigger a severe inflammatory reaction in the brain. A pharmacovigilance study found that serious encephalopathy was reported far more frequently after ivermectin treatment than after other antiparasitic drugs, especially in sub-Saharan Africa.14PubMed Central. Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World This risk is specific to co-infection with Loa loa and is not relevant for most people taking ivermectin for lice in non-endemic regions, but it explains why mass drug programs in certain African countries screen for these worms before distributing ivermectin.
The Blood-Brain Barrier and Why It Matters
Ivermectin’s safety in mammals hinges on a protein called P-glycoprotein, which sits in the walls of blood vessels feeding the brain and actively pumps ivermectin back out before it can enter brain tissue. This barrier is the reason a drug that paralyzes invertebrate nervous systems is well tolerated in people at normal doses.15PubMed Central. Ivermectin: does P-glycoprotein play a role in neurotoxicity? In animal models lacking functional P-glycoprotein (such as certain dog breeds with a mutation in the MDR1 gene), ivermectin readily enters the brain and causes severe neurological toxicity, including tremors, disorientation, and coma.16PubMed. Moxidectin has a lower neurotoxic potential but comparable brain penetration in P-glycoprotein-deficient CF-1 mice compared to ivermectin
In humans, genetic variations that reduce P-glycoprotein function exist but are rare. Certain medications can also inhibit P-glycoprotein, which theoretically could increase ivermectin’s entry into the brain if taken together.17PubMed. Ivermectin: a mini-review This is one reason why the drug should be used under medical supervision rather than self-prescribed, and why keeping to the standard dose is important. The toxicity pathway through mammalian brain GABA receptors has been confirmed in animal knockout models, reinforcing that the protective pump is the critical safety mechanism.18PLOS Neglected Tropical Diseases. Relative Neurotoxicity of Ivermectin and Moxidectin in Mdr1ab (−/−) Mice and Effects on Mammalian GABA(A) Channel Activity
What Happens in an Overdose
At therapeutic doses, serious problems are vanishingly rare. Overdose is a different story. Symptoms of ivermectin neurotoxicity include lethargy, tremors or seizures, impaired balance, confusion, and decreased consciousness. Non-neurological signs can include nausea, vomiting, diarrhea, low blood pressure when standing, and skin reactions.19PubMed Central. Identifying the Toxidrome of Ivermectin Toxicity There is no specific antidote; treatment is supportive, meaning doctors manage symptoms while the body clears the drug. Activated charcoal may help speed elimination if given early.
A comprehensive review of ivermectin toxicity in humans and animals noted that while neurotoxicity at lower exposures tends to be functional and reversible, high or cumulative dosing can cause structural damage to nervous tissue and multi-organ injury.20PubMed Central. Ivermectin Toxicity in Humans and Animals: Clinical Spectrum, Mechanisms, and Management The practical takeaway: ivermectin at the dose used for lice (200 micrograms per kilogram, one or two doses) sits well within the safe range for healthy people. Danger arises from taking far more than prescribed, from using veterinary formulations concentrated for large animals, or from impaired P-glycoprotein function.
Who Should Avoid Ivermectin
Pregnant women are currently excluded from ivermectin treatment programs because safety data during pregnancy are limited. Animal studies at doses far above what humans receive have shown birth defects, and while no comparable harm has been demonstrated in humans, the precautionary exclusion stands.21PubMed Central. Treatment of Pregnant Women with Ivermectin during Mass Drug Distribution: Time to Investigate Its Safety and Potential Benefits Breastfeeding women should also exercise caution, since ivermectin does pass into breast milk in small amounts. Children under 15 kilograms (roughly 33 pounds) are generally excluded from oral ivermectin because dosing data in this weight range are scant.13Journal of Antimicrobial Chemotherapy. Safety of high-dose ivermectin: a systematic review and meta-analysis The topical lotion, by contrast, has safety data supporting use in children as young as six months.11PubMed. Pharmacokinetics and safety of 0.5% ivermectin lotion for head louse infestations
People taking medications that inhibit P-glycoprotein should mention it to their prescriber. Some common drugs in this category include certain heart rhythm medications and immunosuppressants. The interaction risk is theoretical for a short course of ivermectin at lice doses, but it is worth flagging.
Are Lice Becoming Resistant to Ivermectin?
Resistance to permethrin, the active ingredient in most over-the-counter lice shampoos, is already widespread. Head lice in many parts of the United States carry mutations that make them virtually immune to permethrin.22ScienceDirect. Human lice: Past, present and future control That resistance is a big part of why prescribers reach for ivermectin in the first place. But there are early warning signs that ivermectin resistance is developing too.
A trial in rural Senegal found that about 8% of treated patients appeared to have ivermectin-resistant head lice.23PubMed. Assessment of oral ivermectin versus shampoo in the treatment of pediculosis (head lice infestation) in rural areas of Sine-Saloum, Senegal Follow-up genetic analysis of those resistant lice identified three mutations in the GluCl gene, the very receptor ivermectin targets.24PubMed. Mutations in GluCl associated with field ivermectin-resistant head lice from Senegal In body lice, researchers found that a protein called complexin was significantly reduced in ivermectin-resistant strains, and when they experimentally knocked down complexin in susceptible lice, those lice became resistant.25PubMed Central. Complexin in ivermectin resistance in body lice Additional lab work showed that even brief exposure to low, non-lethal amounts of ivermectin activates detoxification genes in body lice, essentially training them to break down the drug faster.26PubMed Central. Brief exposures of human body lice to sublethal amounts of ivermectin over-transcribes detoxification genes involved in tolerance
Resistance is not yet a practical clinical problem in most of the world. The mutations identified in Senegal have not been reported in European or North American lice populations so far. But the pattern mirrors what happened with permethrin resistance, which started with isolated reports and eventually became near-universal. This is a reason to use ivermectin judiciously rather than as a first resort when cheaper, effective options are still working.
Mass Drug Administration and Unexpected Lice Benefits
Ivermectin is distributed on a massive scale in parts of Africa, Asia, and the Pacific to combat parasitic worm diseases. These mass drug campaigns have sometimes produced a welcome side effect: drops in lice and scabies rates in the treated communities.
A cluster randomized trial in Mozambique, where ivermectin was being distributed for malaria research, found that participants who took the drug had dramatically lower odds of having head lice three months later, with the benefit growing after each consecutive monthly round of treatment.27PubMed Central. Collateral benefits of ivermectin mass drug administration designed for malaria against headlice in Mopeia, Mozambique: a cluster randomised controlled trial In the Solomon Islands and Fiji, national scabies mass drug campaigns using ivermectin brought scabies prevalence down from over 23% to under 4% in the Solomons, with parallel drops in the skin infections that scabies enables.28Nature Health. Scabies and impetigo prevalence following ivermectin-based mass drug administration campaigns in Solomon Islands and Fiji
These findings underscore that ivermectin’s broad antiparasitic activity can yield community-level benefits beyond the primary target when enough people in a population receive treatment. For lice specifically, the implication is that oral ivermectin does not just treat individuals; repeated rounds can suppress transmission across a community by reducing the reservoir of infested people at any given time. This strategy is being explored as a potential complement to hygiene education in settings where head lice prevalence is very high and access to topical treatments is limited.